Simvastatin improves learning and memory impairment via gut-brain axis regulation in an ovariectomized/D-galactose Alzheimer's rat model

Zahedi, Elham; Sanaeierad, Ashkan; Nikbakhtzadeh, Marjan; Roghani, Mehrdad; Zamani, Elham

doi:10.1016/j.bbr.2023.114611

Cited by 6 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both atorvastatin and rosuvastatin increase the abundance of butyrate-producing bacteria, such as Butyricimonas , Bacteroides , and Mucispirillum , leading to reduced IL-1β levels and improved inflammation [ 262 ]. Oral administration of simvastatin has been demonstrated to enhance gut microbial activity, increase SCFAs levels in feces, strengthen intestinal cell connections, and reduce cell death and amyloid plaque deposition in the hippocampal tissue [ 263 ]. As showed in Table 2 .…”

Section: Molecular Mechanisms Of Gut Microbiota Regulation Of Ad Lipi...mentioning

confidence: 99%

Gut microbiota-host lipid crosstalk in Alzheimer’s disease: implications for disease progression and therapeutics

Luo,

Yang,

Yao

2024

Mol Neurodegeneration

View full text Add to dashboard Cite

Trillions of intestinal bacteria in the human body undergo dynamic transformations in response to physiological and pathological changes. Alterations in their composition and metabolites collectively contribute to the progression of Alzheimer’s disease. The role of gut microbiota in Alzheimer’s disease is diverse and complex, evidence suggests lipid metabolism may be one of the potential pathways. However, the mechanisms that gut microbiota mediate lipid metabolism in Alzheimer’s disease pathology remain unclear, necessitating further investigation for clarification. This review highlights the current understanding of how gut microbiota disrupts lipid metabolism and discusses the implications of these discoveries in guiding strategies for the prevention or treatment of Alzheimer’s disease based on existing data.

show abstract

Section: Molecular Mechanisms Of Gut Microbiota Regulation Of Ad Lipi...mentioning

confidence: 99%

Gut microbiota-host lipid crosstalk in Alzheimer’s disease: implications for disease progression and therapeutics

Luo,

Yang,

Yao

2024

Mol Neurodegeneration

View full text Add to dashboard Cite

show abstract

“…A preclinical study Statins may improve gut-brain axis followed by decrease in cell death and amyloid plaques via an anti-inflammatory effect. Zahedi et al [122] A retrospective study Long-term statin use for >4 years reduces the risk of motor progression. Palermo et al [123] An explorative study Hydrophilic statins significantly increase clinical and imaging progression in patients with neurodegenerative diseases.…”

Section: Potential and Controversy Of Statins In Ad Treatmentmentioning

confidence: 99%

Mechanisms of 3-Hydroxyl 3-Methylglutaryl CoA Reductase in Alzheimer’s Disease

Zhou,

Wu,

Wang

et al. 2023

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the most common neurodegenerative disease worldwide and has a high incidence in the elderly. Unfortunately, there is no effective therapy for AD owing to its complicated pathogenesis. However, the development of lipid-lowering anti-inflammatory drugs has heralded a new era in the treatment of Alzheimer’s disease. Several studies in recent years have shown that lipid metabolic dysregulation and neuroinflammation are associated with the pathogenesis of AD. 3-Hydroxyl 3-methylglutaryl CoA reductase (HMGCR) is a rate-limiting enzyme in cholesterol synthesis that plays a key role in cholesterol metabolism. HMGCR inhibitors, known as statins, have changed from being solely lipid-lowering agents to neuroprotective compounds because of their effects on lipid levels and inflammation. In this review, we first summarize the main regulatory mechanism of HMGCR affecting cholesterol biosynthesis. We also discuss the pathogenesis of AD induced by HMGCR, including disordered lipid metabolism, oxidative stress, inflammation, microglial proliferation, and amyloid-β (Aβ) deposition. Subsequently, we explain the possibility of HMGCR as a potential target for AD treatment. Statins-based AD treatment is an ascent field and currently quite controversial; therefore, we also elaborate on the current application prospects and limitations of statins in AD treatment.

show abstract

HMG-CoA reductase inhibitor simvastatin ameliorates trimethyltin neurotoxicity and cognitive impairment through reversal of Alzheimer’s-associated markers

Salari,

Roghani,

Khalili

2024

Metab Brain Dis

View full text Add to dashboard Cite

Simvastatin improves learning and memory impairment via gut-brain axis regulation in an ovariectomized/D-galactose Alzheimer's rat model

Cited by 6 publications

References 33 publications

Gut microbiota-host lipid crosstalk in Alzheimer’s disease: implications for disease progression and therapeutics

Gut microbiota-host lipid crosstalk in Alzheimer’s disease: implications for disease progression and therapeutics

Mechanisms of 3-Hydroxyl 3-Methylglutaryl CoA Reductase in Alzheimer’s Disease

HMG-CoA reductase inhibitor simvastatin ameliorates trimethyltin neurotoxicity and cognitive impairment through reversal of Alzheimer’s-associated markers

Contact Info

Product

Resources

About